Results 51 to 60 of about 12,575 (207)

‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily [PDF]

, 2014
Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological ...
P Verboven, CD Zorrilla, Falcon, R, R Wright, Verboven, P, K Brown, Wright, R, Coate, B, B Coate, Kakuda, T N, Yasin, S, Zorrilla, C D, S Yasin, J Mrus, OO Osiyemi, R Falcon, Osiyemi, O O, Baugh, B, Brown, K, Mrus, J, B Baugh, TN Kakuda   +21 more
core   +1 more source

Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir [PDF]

, 2021
Objectives Cobicistat and ritonavir have different inhibitory profiles for drug transporters that could impact the distribution of co-administered drugs.
Bartels, Hanni, Decosterd, Laurent, Battegay, Manuel, Marzolini, Catia   +3 more
core  

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil

Brazilian Journal of Infectious Diseases, 2013
Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil.
José Ernesto Vidal, Alice Tung Wan Song, Maria Laura Matos, Daniel Bartmann, Guilherme dos Anjos, Érique José Peixoto de Miranda, Ângela Carvalho Freitas, Mirian de Freitas Dalben, Claudinei Santana, Aluísio Cotrim Segurado, Cláudia Cortese Barreto, Adrián Vladimir Hernández   +11 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Factors associated with the number of drugs in darunavir/cobicistat regimens. [PDF]

, 2019
Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens.
Knobel, Hernando, Torralba, Miguel, Negredo, Eugenia, Boix, Vicente, Martinez, Esteban, González-Doménech, Carmen María, Ocampo, Antonio, Payeras, Antoni, Alejos, Belén, Martin-Carbonero, Luz, Pérez-Elías, María Jesús, Lozano, Fernando, Montero, Marta, Gutierrez, Mar, Sanz, José, González-Cordón, Ana, Garcia-Fraile, Lucio   +16 more
core   +1 more source

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV [PDF]

, 2021
OBJECTIVE: To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared to postpartum and in infant washout samples after delivery. DESIGN: Nonrandomized, open-label, parallel-group, multi-center phase-IV prospective study of darunavir
RUNGRUENGTHANAKIT, Kittipong, Mark Mirochnick, Kayla Denson, Mary E. Paul, Sandra Burchett, MOMPER, Jeremiah D., Best, Brookie M, Alice Stek, SHAPIRO, David E., David E. Shapiro, BEST, Brookie M., Jeremiah D. Momper, BURCHETT, Sandra, YANG, Derek, Yang, Derek Z, CAPPARELLI, Edmund V., WANG, Jiajia, Kathleen George, STEK, Alice, Capparelli, Edmund V, CHAKHTOURA, Nahida, DENSON, Kayla, Momper, Jeremiah D, Shapiro, David E, FEBO, Irma L., PAUL, Mary E., SMITH, Elizabeth, Jiajia Wang, Kittipong Rungruengthanakit, Nahida Chakhtoura, Gwendolyn B. Scott, Irma L. Febo, Brookie M. Best, Elizabeth Smith, Febo, Irma L, Derek Z. Yang, GEORGE, Kathleen, Edmund V. Capparelli, SCOTT, Gwendolyn B., Scott, Gwendolyn B, Paul, Mary E, MIROCHNICK, Mark   +41 more
core   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction [PDF]

, 2011
The present study aimed to investigate potential drug interactions between darunavir and raltegravir in patients treated for HIV infection. We enrolled HIV-infected subjects on darunavir-containing regimens that underwent measurement of plasma darunavir ...
Fabbiani, Massimiliano, Bracciale, Laura, Pierluigi Navarra, Parruti, Giustino, CAUDA R., Prosperi, Mattia, D'ETTORRE G., DE LUCA A., Laura Bracciale, FABBIANI M., BRACCIALE L., PARRUTI G., Massimiliano Fabbiani, NAVARRA P., Cauda, Roberto, Di Giambenedetto, Simona, Enzo Ragazzoni, DI GIAMBENEDETTO S., Giustino Parruti, RAGAZZONI E., Mattia Prosperi, Simona Di Giambenedetto, Gabriella D’Ettorre, Roberto Cauda, Andrea De Luca, De Luca, Andrea, Navarra, Pierluigi, Ragazzoni, Enzo, D'Ettorre, Gabriella, PROSPERI M.   +29 more
core   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, Volume 27, Issue 7, Page 1132-1143, July 2026.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source